



Exome-wide association study of plasma lipids in >300,000 individuals

Citation

Liu, D. J., G. M. Peloso, H. Yu, A. S. Butterworth, X. Wang, A. Mahajan, D. Saleheen, et al. 2017. "Exome-wide association study of plasma lipids in >300,000 individuals." *Nature genetics* 49 (12): 1758-1766. doi:10.1038/ng.3977. <http://dx.doi.org/10.1038/ng.3977>.

Published Version

doi:10.1038/ng.3977

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:37068188>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Nat Genet. 2017 December ; 49(12): 1758–1766. doi:10.1038/ng.3977.

Exome-wide association study of plasma lipids in >300,000 individuals

A full list of authors and affiliations appears at the end of the article.

Abstract

We screened DNA sequence variants on an exome-focused genotyping array in >300,000 participants with replication in >280,000 participants and identified 444 independent variants in 250 loci significantly associated with total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and/or triglycerides (TG). At two loci (*JAK2* and *AICF*), experimental analysis in mice revealed lipid changes consistent with the human data. We utilized mapped variants to address four clinically relevant questions and found the following: (1) beta-thalassemia trait carriers displayed lower TC and were protected from coronary artery disease; (2) outside of the *CETP* locus, there was not a predictable relationship between plasma HDL-C and risk for age-related macular degeneration; (3) only some mechanisms of lowering LDL-C seemed to increase risk for type 2 diabetes; and (4) TG-lowering alleles involved in hepatic production of TG-rich lipoproteins (e.g., *TM6SF2*, *PNPLA3*) tracked with higher liver fat, higher risk for type 2 diabetes, and lower risk for coronary artery disease whereas

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspondence to: Cristen Willer, cristen@umich.edu; Sekar Kathiresan, SKATHIRESAN1@mgh.harvard.edu.

†These authors contributed equally.

URLS

1. Full meta-analysis results are available at <http://csg.sph.umich.edu/abecasis/public/lipids2017/>
2. Michigan Genomics Initiative (www.michigangenomics.org)

Author Contributions:

All authors contributed to and approved the results and comments on the manuscript.

Writing Group: C.J.W., D.J.L., G.M.P., G.A., P.D., X.L., S.K.

Study supervision: S.K.

Primary Analysis: D.J.L., G.M.P.

Secondary Analysis: A.K., A.Mahajan, C.M.M., C.E., D.J.R., D.R., D.P., E.K.S., E.M.S., J.B.M., J.Wessel, L.F., M.G., M.I.M., M.Boehnke, N.Stitzel, R.S.S., S.Somayajula, X.L.

Functional Characterization: A.R.T., C.Cowan, H.Yu, K.M., N.W., X.W.

Contributed to Study Specific Analysis: A.B., A.C.A., A.C.M., A.D., A.F., A.K.M., A.Langsted, A.Linneberg, A.Malarstig, A.Manichaikul, A.Maschio, A.Metspalu, A.Mulas, A.P., A.P.M., A.P.P., A.P.R., A.R., A.T., A.U.J., A.V., A.V.S., A.Y.C., B.G.N., B.H.S., B.M.P., C.Christensen, C.G., C.H., C.J.O., C.J.W., C.L., C.L.K., C.M.B., C.M.S., C.N.A.P., C.P., D.Alam, D.Arveiler, D.C.L., D.I.C., D.J.L., D.K., D.M.R., D.S., E.B., E.C., E.d.A., E.M., E.P.B., E.Z., F.B., F.C., F.G., F.Karpe, F.Kee, F.R., G.B.J., G.Davies, G.Dedoussis, G.E., G.M.P., G.P., H.A.K., H.G., H.M.S., H.R.W., H.Tada, H.Tang, H.Yaghootkar, H.Z., I.B., I.F., I.J.D., I.R., J.W.B., J.C.B., J.C.C., J.C.D., J.D., J.D.R., J.F., J.G.W., J.H., J.I.R., J.J., J.K., J.M.C., J.M.H., J.M.J., J.M.O., J.M.S., J.N., J.N.H., J.S.K., J.Tardif, J.Tuomilehto, J.V., J.Weinstock, J.W.J., K.D.T., K.E.S., K.H., K.K., K.S., K.S.S., L.A.C., L.A.L., L.E.B., L.G., L.J.L., L.S., M.Benn, M.Brown, M.C., M.D., M.E.G., M.E.J., M.Ferrario, M.F.F., M.Fornage, M.J., M.J.N., M.L., M.L.G., M.M., M.O., M.P., M.W., M.X., M.Z., N.G., N.G.M., N.J.S., N.J.W., N.P., N.R.R., N.R.v.Z., N.Sattar, N.S.Z., O.L.H., O.M., O.Pedersen, O.Polasek, P.A., P.B.M., P.D., P.E.W., P.F., P.L.A., P.Mäntyselkä, P.M.R., P.Muntendam, P.R.K., P.Sever, P.S.T., P.Surendran, P.W.F., P.W.W., R.A.S., R.C., R.F., R.J.L., R.M., R.R., R.Y., S., S.F.N., S.J., S.Kanoni, S.Kathiresan, S.K.G., S.M.D., S.Sanna, S.Sivapalaratnam, S.S.R., S.T., T.B.H., T.D.S., T.Ebeling, T.E.c., T.Esko, T.H., T.L.A., T.Lakka, T.Lauritzen, T.M.F., T.V.V., U.B., V.F., V.G., V.S., W.G., W.Zhang, W.Zhou, X.S., Y.E.C., Y.H., Y.I.C., Y.L., Y.Zhang, Y.Zhou

Data Availability Statement

The meta-analysis summary association statistics that support the findings of this study are available from <http://csg.sph.umich.edu/abecasis/public/lipids2017/>

TG-lowering alleles involved in peripheral lipolysis (e.g., *LPL*, *ANGPTL4*) had no effect on liver fat but lowered risks for *both* type 2 diabetes and coronary artery disease.

Plasma lipid levels are modifiable risk factors for atherosclerotic cardiovascular disease. Genome-wide association studies (GWAS) testing common DNA sequence variation have uncovered 175 genetic loci affecting lipid levels¹ in the population^{2–8}. These findings have informed biology of lipoproteins and elucidated the causal roles of lipid levels on cardiovascular disease^{9–12}. Here, we build on these previous efforts to: 1) perform an exome-wide association screen for plasma lipids in >300,000 individuals; 2) evaluate discovered alleles experimentally; and 3) test the inter-relationship of mapped lipid variants with coronary artery disease (CAD), age-related macular degeneration (AMD), fatty liver, and type 2 diabetes (T2D).

We tested the association of genotypes from the HumanExome BeadChip (i.e., exome array) with lipid levels in 73 studies encompassing >300,000 participants (Supplementary Material, Supplementary Tables 1–3) across several ancestries with the maximal sample sizes being 237,050 for European, 16,935 for African, 37,613 for South Asian, and 5,082 for Hispanic or other. A companion manuscript describes results for 47,532 East Asian participants¹³. A total of 242,289 variants were analyzed after quality control, about one-third of which are non-synonymous with minor allele frequency (MAF) < 0.1% (Supplementary Table 4).

Single-variant association statistics and linkage disequilibrium information summarized across 1 megabase sliding windows were generated from each cohort using RAREMETALWORKER or RVTESTS^{14,15} software. Meta-analyses of single variant and gene-level association tests were performed using rareMETALS (version 6.0). Genomic control values for meta-analysis results were between 1.09 and 1.14 for all four traits (Supplementary Figure 1), suggesting that population structure in our analysis is well-controlled^{4,16}.

We identified 1,445 single variants associated at $P < 2.1 \times 10^{-7}$ (Bonferroni correction of 242,289 variants analyzed) (Supplementary Figures 2–5). Full association results are available (see URLs). Of these, 75 were ‘novel’ [i.e. located at least 1 megabase from previously reported GWAS signals]: 35 of these were protein-altering variants and 40 were non-coding variants (Table 1, Supplementary Tables 5–7). The MAF of the lead variant was >5% at 61 of these 75 loci. European ancestry participants provided the most significant associations for the 75 novel loci, with the exception of two LDL associated variants (rs201148465 and rs147032017) which were driven by the South Asian participants (Supplementary Table 8). Gene-level association analyses revealed an additional five genes where the signal was driven by multiple rare variants ($P < 4.2 \times 10^{-7}$, Bonferroni correction threshold for performing 5 tests on ~20,000 genes, Supplementary Table 9).

We sought replication in up to 286,268 independent participants from three studies – Nord-Trøndelag Health Study¹⁷, (HUNT; max n = 62,168), Michigan Genomics Initiative (MGI; max n = 6,411, see URLs) and the Million Veteran Program¹⁸ (MVP; max n = 218,117). Of the novel primary trait associations, 73/73 associations were directionally consistent (Supplementary Table 10); two SNPs were not available for replication (rs201148465,

rs75862065). Furthermore, we were able to replicate the associations of 66/73 (90%) at $\alpha=0.05$.

At any given genetic locus, multiple variants may independently contribute to plasma lipid levels. We quantified this phenomenon by iteratively performing association analyses conditional on the top variants at each locus. We identified 444 variants independently associated with one or more of the four lipid traits in 75 novel and 175 previously implicated loci (Supplementary Figure 6; Supplementary Table 11–12).

The identification of lipid-associated coding variants may help refine association signals at previously identified GWAS loci. We were able to evaluate this possibility in 131 of the 175 previously reported GWAS loci where the index or proxy variant was available on the exome array, and associated with lipids levels with $P < 2.1 \times 10^{-7}$ (Supplementary Table 13–14). For example, an intronic SNP (rs11136341, close to the *PLEC* gene) associated with LDL-C was the original lead SNP in its GWAS locus ($P = 2 \times 10^{-13}$). In the current study, a protein-altering variant in *PARP10* is the top variant in the same locus (rs11136343; Leu395Pro; $P = 7 \times 10^{-26}$). After conditioning on *PARP10* Leu395Pro, the evidence for rs11136341 diminished ($P = 0.02$); in contrast, *PARP10* Leu395Pro remained significant ($P = 9 \times 10^{-13}$) after conditioning on rs11136341. *PARP10* has been shown to affect the hepatic secretion of apolipoprotein B (apoB) in human hepatocytes¹⁹; these results prioritize *PARP10* as a causal gene at this locus.

Experimental analysis of discovered mutations in model systems is a powerful approach to validate the results of a human genetics analysis. We prioritized two coding mutations for experimental analysis: *JAK2* (Janus Kinase 2) p.Val617Phe and *AICF* (APOBEC1 complementation factor) p.Gly398Ser.

JAK2 p.Val617Phe is a recurrent somatic mutation arising in hematopoietic stem cells which can lead to myeloproliferative disorders or clonal hematopoiesis of indeterminate potential^{20–24}. We recently showed that carriage of p.Val617Phe increases with age and confers higher risk for CAD²⁵. Surprisingly, the 617Phe allele which increases risk for CAD is associated with lower LDL-C. Mice knocked in for *Jak2* p.Val617Phe were created as reported previously²⁶. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from *Jak2* p.Val617Phe transgenic mice displayed lower total cholesterol than mice that had received control bone marrow (Supplementary Figure 7). This is consistent with our human genetic observations. The mechanism by which *JAK2* p.Val617Phe leads to lower plasma TC and LDL-C but higher risk for CAD requires further study.

Another new association to emerge from genetic analyses was between *AICF* p.Gly398Ser and TG [MAF 0.7%, 0.10-standard deviation (SD) increase in TG per copy of alternate allele, $P = 4 \times 10^{-11}$]; this variant was also associated with increased circulating TC ($P = 4 \times 10^{-7}$) and nominally associated with increased risk of CAD (OR=1.12; $P = 0.02$). *AICF* encodes APOBEC1 complementation factor, an RNA-binding protein which facilitates the RNA-editing action of APOBEC1 on the *APOB* transcript^{27,28}. We performed

CRISPR-Cas9 deletion, rescue, and knock-in experiments to assess whether *A1CF* p.Gly398Ser is a causal mutation that alters TG metabolism.

CRISPR-Cas9-induced deletion of *A1CF* led to 72% and 65% reduction in secreted APOB100 compared to control cells in Huh7 and HepG2 human hepatoma cells, respectively (Figure 1A–1C; Supplementary Figure 8). These findings are consistent with previous studies in rat primary hepatocytes that also showed significantly decreased apoB secretion after RNAi-based depletion of *A1CF*²⁹. Additionally, cellular APOB100 levels were significantly reduced in *A1CF*-deficient cells (Supplementary Figure 8B and 8C). A subsequent “rescue” experiment involving overexpression of wild-type or *A1CF* p.Gly398Ser in Huh7 cells with or without endogenous *A1CF* expression confirmed that higher APOB100 secretion in cell lines expressing *A1CF* p.Gly398Ser (Figure 1D).

We sought to further validate the *A1CF* gene and the p.Gly398Ser variant through the use of CRISPR-Cas9 to generate knock-in mice. Using a guide RNA targeting *A1cf* exon 9, the site of the codon for p.Gly398, and a 162-nucleotide single-strand DNA oligonucleotide repair template containing the p.Gly398Ser variant as well as extra synonymous changes to prevent re-cleavage by CRISPR-Cas9, we generated mice of the C57BL/6J inbred background with an *A1cf* Gly398Ser allele (hereafter referred to as KI) (Supplementary Figure 9A, 9B). We bred the KI allele to homozygosity and found that KI/KI mice were viable and healthy. We compared wild-type and KI/KI colony mates (n=9, 8) with respect to TG levels (Supplementary Figure 9C, 9D). We found that KI/KI mice had 46% increased TG compared to wild-type mice ($P=0.05$). In sum, these results indicate that *A1CF* is a causal gene for TG in humans and that the p.Gly398Ser variant is a causal mutation, with possible relevance to CAD.

Next, we used the 444 identified DNA sequence variants to address four clinical questions. First, a rare null mutation in the beta-globin gene (*HBB*; c.92+1G>A, rs33971440) associated with lower total cholesterol (Supplementary Table 15) with the strongest total cholesterol-lowering effect after null mutations in *PCSK9*; this raised the question of the relationship between beta-thalassemia and risk for CAD. Approximately 80 to 90 million individuals worldwide are estimated to carry a heterozygous loss-of-function *HBB* mutation, termed beta-thalassemia trait³⁰. Observational epidemiologic studies showed that beta-thalassemia trait associates with lower blood cholesterol level^{31,32}. We find that *HBB* c.92+1G>A is associated with a 17 mg/dl decrease in LDL-C (95% CI: -23, -11; $P=2.7\times 10^{-8}$) and a 21 mg/dl decrease in TC (95% CI: -27, -14; $P=8.9\times 10^{-11}$) (Supplementary Figure 10). In an analysis of 31,156 CAD cases and 65,787 controls, carriers of loss-of-function variants in *HBB* were protected against CAD (odds ratio for CAD, 0.70; 95% CI 0.54, 0.90; $P=0.005$, Supplementary Figure 11). Of note, in Supplementary Table 15, we provide results for null mutations where association $P<0.001$ for any of the four lipid traits.

Second, DNA sequence variants in the *CETP* gene which associate with higher HDL-C also correlate with higher risk for AMD, a leading cause of blindness^{33–37}; here, we ask if *any way* of increasing *plasma* HDL-C will predictably lead to increased AMD risk. Across 168 independent HDL-C variants with MAF > 1%, we tested the association of each HDL-C

variant with AMD risk. The effect size of variant on HDL-C was positively correlated with its effect on AMD risk (correlation in effect sizes, $r=0.41$, $P=4.4\times 10^{-8}$; Supplementary Table 16, Supplementary Figure 12). However, this effect was driven by the 10 independent HDL-C associated variants in *CETP* (heterogeneity across the different HDL-C-raising mechanisms ($\tau^2 = 0.91$, $P_{\text{het}}=1.8\times 10^{-15}$) (Supplementary Table 17). When these 10 *CETP* variants were removed, there was no longer a relationship between genetically-altered HDL-C and AMD risk ($P=0.17$). These results suggest that outside of the *CETP* locus, there is not a predictable relationship between plasma HDL-C and risk for AMD.

Third, will lowering LDL-C with lipid-modifying medicines always increase risk for T2D? This question is motivated by the fact that in randomized controlled trials, statin therapy increases risk for T2D^{26,27} and recent reports of *PCSK9* variants associating with higher risk for T2D³⁸⁻⁴⁰. We confirmed the association of *PCSK9* p.Arg46Leu (R46L) with risk for T2D among 222,877 participants (Supplementary Table 18). We found that the 46Leu allele associated with lower LDL-C confers a 13% increased risk for T2D (OR 1.13; 95% CI 1.06–1.20; $P=6.96\times 10^{-5}$) (Supplementary Figure 13). In addition, across 113 independent LDL-C variants at 90 distinct loci, we compared each variant's effect on LDL-C with its subsequent effect on risk for T2D. Across the 113 variants, there is a weak inverse correlation between a variant's effects on LDL-C and T2D ($r=-0.21$, $p=0.025$); however, there is evidence for heterogeneity in this relationship ($\tau^2=0.50$, $P_{\text{het}}=2.5\times 10^{-9}$). Five LDL-C lowering genetic mechanisms had the most compelling evidence for association with higher risk for T2D (*TM6SF2* p.Glu167Lys, *APOE* chr19:4510002, *HNF4A* p.Thr136Ile, *PNPLA3* p.Ile148Met, and *GCKR* p.Leu446Pro) ($P<4.0\times 10^{-4}$ for each, Bonferroni correction threshold for performing tests at 113 variants, Supplementary Table 19; Supplementary Figure 14). These results suggest that only some ways of lowering LDL-C are likely to increase risk for T2D.

Finally, two key processes – hepatic production and peripheral lipolysis – contribute to the blood level of TG. We asked how genes involved in hepatic production of TG-rich lipoproteins (*PNPLA3*, *TM6SF2*) differed from lipolysis pathway genes (*LPL*, *ANGPTL4*) in their impact on related metabolic traits - blood lipids, fatty liver, T2D, and CAD (Table 2). The alternative alleles at *PNPLA3* p.Ile148Met, *TM6SF2* p.Glu167Lys, *LPL* p.Ser474Ter, and *ANGPTL4* p.Glu40Lys all associated with lower blood triglycerides and reduced risk for CAD. However, the blood TG-lowering alleles at *PNPLA3* and *TM6SF2* led to more fatty liver and higher risk for T2D. In contrast, the blood triglyceride-lowering alleles at *LPL* and *ANGPTL4* were neutral with respect to fatty liver and led to lower risk for T2D. We confirmed the *LPL* observation using a phenome-wide association study in the UK Biobank (Supplementary Table 20). In UK Biobank, a one-SD decrease in TG mediated by *LPL* variants reduced risks for *both* T2D and CAD (Figure 2).

In summary, combining large-scale human genetic analysis with experimental evidence, we demonstrate: (1) 444 independent coding and non-coding variants at 250 loci as associated with plasma lipids; (2) the use of mouse models and genome editing to pinpoint causal genes and protein-altering variants; and (3) that *LPL* activation can be expected to lower triglycerides and reduce risks for *both* CAD and T2D without increasing liver fat and thus be advantageous for patients with metabolic risk factors.

ONLINE METHODS

Study samples and phenotypes

Seventy-three studies contributed association results for exome chip genotypes and plasma lipid levels. The outcomes were fasting lipid values in mg/dl [TC, HDL-C, LDL-C, TG] from the baseline, or earlier exam with fasting measures. If a study only had non-fasting levels, then it contributed only to the TC and HDL-C analyses. LDL-C and TG analyses were only performed on fasting lipid values. Lipid-lowering therapy with statins was not routinely used prior to the publication of the 4S study in 1994 which demonstrated the clinical benefit of statin therapy. Therefore, for data collected before 1994, no lipid medication adjustment was applied. For data collected after 1994, we adjusted the TC values for individuals on lipid medication by replacing their total cholesterol values by $TC/0.8$; this adjustment estimates the effect of statins on TC values. No adjustment was made on HDL-C or TG. LDL-C was calculated using the Friedewald equation for those with $TG < 400$ mg/dl ($LDL-C = TC - HDL-C - (TG/5)$). If TC was modified as described above for medication use after 1994, then modified TC was used in this formula. If only measured LDL-C was available in a study, we used $LDL/0.7$ for those on lipid-lowering medication when data were collected after 1994. TG values were natural log transformed. For each phenotype, residuals were obtained after accounting for age, age^2 , sex, principal components (as needed by each study, up to four), and inverse normal transform residuals were created for analysis. For studies ascertained on CAD case/control status, the two groups were modeled as separate studies.

Genotyping and quality control

All studies assayed the Illumina or Affymetrix Human Exome array v1 or v1.1. Genotypes were determined from Zcall⁴³ or joint calling⁴⁴. Individual studies performed the following quality control: call rate, heterozygosity, gender discordance, GWAS discordance (if GWAS data available), fingerprint concordance, if available, and PCA outliers.

Association analyses

Each contributing cohort analyzed the ancestries within their cohorts separately and studies collected on case/control status analyzed cases separately from the controls. We performed both single variant and gene-level association tests. In the association analysis, we obtain residuals after controlling for sex, age, age^2 and up to 4 principal components as covariates. Studies that had related samples analyzed the association using linear mixed models with relatedness estimated from genome-wide SNPs or from pedigrees.

From each study, we collected single variant score statistics and their covariance matrix for variants in sliding windows across the genome. Summary association test statistics were generated using RAREMETALWORKER or RVTESTS. Using summary association statistics collected from each study, we performed meta-analysis of single variant association tests using the Mantel-Haenszel test and constructed burden, SKAT and variable threshold tests using the approach by Liu et al¹⁵. For burden and SKAT, we used minor allele frequency thresholds of 1% and 5% and for VT, we applied minor allele frequency threshold

of 5%. In the SKAT test, variants are weighted according to their minor allele frequencies, using the beta kernel $\beta(1,25)$.

Using covariance matrices between single variant association statistics, we were also able to perform conditional association analyses centrally, which distinguishes genuine signals from “shadows” of known loci. Details of the methods can be found in Liu et al¹⁵.

We centrally performed quality control for the data. We aligned study reported reference and alternative alleles with alleles reported in the NHLBI Exome Sequencing Project⁴⁵ and remove mis-labelled variant sites that can be strand ambiguous. For variant sites in each study, we removed variants that had call rate < 0.9 or had Hardy Weinberg P values $< 1 \times 10^{-7}$. Finally, as additional checks, we visually inspected for each study the scatter plot of variant allele frequency against frequencies from ethnicity-matched populations in the 1000 Genomes Project⁴⁶, and made sure that the strand and allele labels were well calibrated between studies.

Single variant associations with $P < 2.1 \times 10^{-7}$ ($0.05/242,289$ variants analyzed) and gene-based associations with $P < 4.2 \times 10^{-7}$ ($0.05/[20,000 \text{ genes} * 6 \text{ tests}]$) were considered significant. Novel loci were defined as being not within 1 megabase of a known lipid GWAS SNP. Additionally, linkage disequilibrium information was used to determine independent SNPs where a locus extended beyond 1 megabase. All novel loci reported in this manuscript are > 1 megabase from any previously reported locus and independent ($r^2 < 0.2$ was required for variants within 3 megabases).

Sequential forward selection

To identify independently associated variants for each known and newly identified locus, we performed sequential forward selection. We initialized the set of independently associated variants (denoted by Φ), starting with the top association signal in the locus. For each iteration, conditioning on variants in Φ , we performed conditional association analyses for all remaining variants. If the top association signal after the conditional analysis remained significant, we added the top variant to the set Φ , and then repeated the conditional association analysis. If the top variant after the conditional analysis was no longer significant, we stopped and reported variants in the set Φ as the final set of independent variants for that locus. We used the same single variant significance threshold ($P < 2.1 \times 10^{-7}$) to determine statistical significance with the sequential forward selection results (Supplementary Figure 3).

Annotation

Sequence variants were annotated according to refSeq version 1.9, using the SEQMINER software (version 5.7)⁴⁷. Transcript level annotations were obtained and prioritized. When multiple transcript level annotations were available, they were prioritized according to their functionality and deleteriousness. To implement gene-level association tests, the annotation with the highest priority was used (along with other filtering criteria such as minor allele frequencies) to determine the set of variants that are included.

Heritability and proportion of variance explained estimates

We estimated the proportion of variance explained by the set of 444 independently associated variants. The joint effects of variants in a locus were approximated by

$\widehat{\beta}_{\text{JOINT}} = \mathbf{V}_{\text{META}}^{-1} \widehat{\mathbf{U}}_{\text{META}}$, where $\widehat{\mathbf{U}}_{\text{META}}$ is the single variant score statistics and $\mathbf{V}_{\text{META}}^{-1}$ is the covariance matrix between them. The covariance between single variant genetic effects was approximated by the inverse of the variance-covariance matrix of score statistics, i.e. $\mathbf{V}_{\text{META}}^{-1}$. The phenotypic variance explained by the independently associated variants in a locus is given by $\widehat{\beta}_{\text{JOINT}}^T \text{COV}(\mathbf{G}) \widehat{\beta}_{\text{JOINT}}$, where \mathbf{G} is the genotypes of the analyzed variants.

Refinement of genome-wide association signals

We sought to quantify what proportion of GWAS loci might be due to a protein-altering variant and, therefore, directly identify a functional gene. We made the assumption that a protein-altering variant is the most likely causal variant for each region if it is the top signal, explains the signal, or is independent of the original signal. To identify putative functional coding variants accounting for the effects at known lipid loci, we performed reciprocal conditional analyses to control for the effects of known lipid GWAS or coding variants within 500kb, as this was the maximum distance for variants within the covariance matrix. Loci where coding variants are the most significant signals were considered as “coding as top”. Loci where the initial GWAS variants had conditional $P > 0.01$ were considered to be explained by the coding variants. Loci where the coding variants had conditional $P < 2.1 \times 10^{-7}$ were considered to be independent of the initial GWAS signals.

JAK2 p.Val617Phe and plasma cholesterol in a mouse model

Jak2 p.Val617Phe MxCre mice were created and reported previously²⁶. Bone marrow cells from the WT or *JAK2* p.Val617Phe MxCre mice, both treated with poly I:C, were transplanted into irradiated *Ldlr*^{-/-} recipients. After four weeks of recovery, the *Ldlr*^{-/-} recipient mice were fed a Western diet (TD88137, Harlan Teklad) for 8 weeks. Plasma was collected and 250 microliter of pooled plasma from 7 WT → *Ldlr*^{-/-} or 7 *Jak2* Val617Phe → *Ldlr*^{-/-} recipient was subjected to fast protein liquid chromatography on Sepharose CL-6B size exclusion column. Total cholesterol content in each fraction was assessed by Cholesterol E kit (Wako Diagnostics).

Validation of A1CF with CRISPR-Cas9 in human cells

To knock out *A1CF* in Huh7 and HepG2 human hepatoma cells, three CRISPRs (Supplementary Table 21) targeting exon 4 of the *A1CF* gene were constructed by using the lentiviral vector lentiGuide-Puro. Packaged viruses were used to transduce the cells expressing Cas9 for 16 hours. Subsequently, cells were cultured in the presence of 5 µg/ml puromycin for five days before splitting for assays. Cells for APOB secretion assay were cultured for 18 hours in serum-free medium, then the amount of APOB100 in medium was measured using an ELISA kit (MABTECH) according to the manufacturer’s instructions.

In a rescue experiment, to avoid cutting of the *A1CF* coding region on the recombinant plasmids by previously designed exon-targeting CRISPRs, four new CRISPRs targeting

introns flanking exon 4 were applied to deplete endogenous *AICF*. The sequences for those sgRNAs are available in Supplementary Table 21. The *AICF*p.Gly398Ser variant was generated by using overlapping PCR and confirmed by Sanger sequencing. Both wild-type and the *AICF*p.Gly398Ser variant were constructed into lentiviral plasmids, respectively. After transduction, cells were cultured for 48 hours in the presence of 100 ng/ml doxycycline to induce recombinant expression of A1CF or p.Gly398Ser variant before performing different assays.

A1cf p.Gly390Ser knock-in mice

All procedures used for animal studies were approved by Harvard University's Faculty of Arts and Sciences Institutional Animal Care and Use Committee and were consistent with local, state, and federal regulations as applicable. Knock-in mice were generated using a guide RNA designed to target the orthologous site of the *AICF*p.Gly390Ser variant. In vitro transcribed Cas9 mRNA (100 ng/ μ L; TriLink BioTechnologies) and guide RNA (50 ng/ μ L) were co-injected with 100 ng/ μ L single-strand DNA oligonucleotide (Integrated DNA Technologies): (Supplementary Table 21) into the cytoplasm of fertilized oocytes from C57BL/6J mice. Genomic DNA samples from founder mice were screened for knock-in mutations by PCR and confirmed by Sanger sequencing. Positive mice were bred with C57BL/6J mice to generate wild-type and homozygous knock-in mice. Male colony mates at 12 weeks of age were used for lipid measurements. Blood samples were collected from the lateral tail vein following an overnight fast. Plasma triglyceride levels were measured using Infinity Triglycerides Reagent (Thermo Fisher) according to the manufacturers' instructions.

Intersection of lipid association signals with AMD, CAD, and T2D

To estimate the association of loss-of-function variants in *HBB* with cholesterol levels, participants from the following two consortia were studied: the Global Lipids Genetics Consortium and the Myocardial Infarction Genetics Consortium (MIGen, 27,939 participants in 12 cohorts). A rare loss-of-function variant in *HBB* (c.92+1G>A, rs33971440) was genotyped in participants from the Global Lipids Genetics Consortium Exome consortium. This variant was pooled with sequence data for the *HBB* gene in MIGen, available in 19,434 participants with blood cholesterol measurements. The association of loss-of-function variants with cholesterol was estimated using linear regression with adjustment for age, sex and up to five principal components of ancestry. Estimates from genotyped and sequence data were pooled using inverse variance weighted fixed effects meta-analysis.

To estimate the association of loss-of-function variants in *HBB* with CAD, participants from the following two consortia were studied: the CARDIoGRAM Exome Consortium (69,087 participants from 20 studies) and MIGen (12,384 CAD cases and 15,547 controls from 12 studies). 69,086 individuals who were genotyped for the c.92+1G>A variant in CARDIoGRAM Exome were pooled with sequence data for *HBB* from 27,931 individuals in MIGen. The association of loss-of-function variants with CAD was estimated using logistic regression with adjustment for age, sex and up to five principal components of ancestry. Estimates were pooled using inverse variance weighted fixed effects meta-analysis. To estimate the association of loss of function variants in *HBB* with hemoglobin and

hematocrit levels, estimates from an exome chip analysis of red blood cell traits (24,814 individuals) were used⁸.

For 168 variants independently and significantly associated with HDL-C and a MAF > 1%, we looked up the association evidence in 16,144 AMD cases and 17,832 controls with exome chip genotypes⁴⁸.

For 132 independently and significantly associated LDL-C variants and MAF > 1%, we looked up the association evidence in: (1) up to 120,575 individuals with and without CAD and exome chip genotypes (42,335 cases and 78,240 controls)⁴²; and (2) up to 69,870 individuals with and without type 2 diabetes. Only 113 of the 132 LDL variants were available in the type 2 diabetes results. We used a Bonferroni correction for 132 variants to determine significance of the results ($\alpha = 4.0 \times 10^{-4}$).

Association of *PCSK9* R46L with type 2 diabetes

For evaluating the association of *PCSK9* R46L with risk of type 2 diabetes, we considered a total of 42,011 type 2 diabetes cases and 180,834 controls from 30 studies from populations of European ancestry (Supplementary Table 18). The variant was directly genotyped in all studies using the MetaboChip or the Exome array. Sample and variant quality control was performed within each study as described previously^{49–52}. Within each study, the variant was tested for association with type 2 diabetes under an additive model after adjustment for study-specific covariates, including principal components to adjust for population structure. Association summary statistics for the variant for each study was corrected for residual population structure using the genomic control inflation factor as described previously^{49–51}. We then combined association summary statistics for the variant across studies via fixed-effects inverse-variance weighted meta-analysis.

TG variants, lipids, fatty liver, type 2 diabetes, and CAD

Exome chip results for four variants (*LPL* p.Ser474Ter [rs328], *ANGPTL4* p.Glu40Lys [rs116843064], *PNPLA3* p.Ile148Met [rs738409], and *TM6SF2* p.Glu167Lys [rs58542926]) were obtained from the following sources:

1. lipids: current analysis
2. fatty liver: Between 2002 and 2005, 1,400 individuals from the Framingham Offspring Study and 2,011 individuals from third generation underwent multi-detector computed tomograms (CT) on which we evaluated liver attenuation as previously described⁵³. We tested the association of TG variants with CT liver fat after inverse normal transformation. Covariates in the regression models included age, age², and gender. A similar analysis was conducted in 3,293 participants of European ancestry from BioImage study⁵⁴. Association results for liver attenuation from the Framingham and BioImage studies were combined through fixed-effects inverse-variance weighted meta-analysis.
3. type 2 diabetes: ExTexT2D Consortium⁴¹

4. CAD: published results from the Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia study⁴² and analysis of the UK Biobank combined through meta-analysis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Dajiang J. Liu^{1,†}, Gina M. Peloso^{2,3,†}, Haojie Yu^{4,†}, Adam S. Butterworth^{5,6,†}, Xiao Wang^{7,†}, Anubha Mahajan^{8,†}, Danish Saleheen^{5,9,10,†}, Connor Emdin^{3,11,†}, Dewan Alam¹², Alexessander Couto Alves¹³, Philippe Amouyel¹⁴, Emanuele di Angelantonio^{5,6}, Dominique Arveiler¹⁵, Themistocles L. Assimes^{16,17}, Paul L. Auer¹⁸, Usman Baber¹⁹, Christie M. Ballantyne²⁰, Lia E. Bang²¹, Marianne Benn^{22,23}, Joshua C. Bis²⁴, Michael Boehnke²⁵, Eric Boerwinkle^{26,27}, Jette Bork-Jensen²⁸, Erwin P. Bottinger²⁹, Ivan Brandslund^{30,31}, Morris Brown³², Fabio Busonero³³, Mark J Caulfield^{34,35}, John C Chambers^{36,37,38}, Daniel I. Chasman^{39,40}, Y. Eugene Chen⁴¹, Yii-Der Ida Chen⁴², Rajiv Chowdhury⁵, Cramer Christensen⁴³, Audrey Y. Chu^{39,44}, John M Connell⁴⁵, Francesco Cucca^{33,46}, L. Adrienne Cupples^{2,44}, Scott M. Damrauer^{47,48}, Gail Davies^{49,50}, Ian J Deary^{49,50}, George Dedoussis⁵¹, Joshua C. Denny^{52,53}, Anna Dominiczak⁵⁴, Marie-Pierre Dubé^{55,56,57}, Tapani Ebeling⁵⁸, Gudny Eiriksdottir⁵⁹, Tõnu Esko^{3,60}, Aliko-Eleni Farmaki⁵¹, Mary F Feitosa⁶¹, Marco Ferrario⁶², Jean Ferrieres⁶³, Ian Ford⁶⁴, Myriam Fornage⁶⁵, Paul W. Franks^{66,67,68}, Timothy M. Frayling⁶⁹, Ruth Frikke-Schmidt^{70,71}, Lars Fritsche²⁵, Philippe Frossard¹⁰, Valentin Fuster¹⁹, Santhi K. Ganesh^{41,72}, Wei Gao⁷³, Melissa E. Garcia⁷⁴, Christian Gieger^{75,76,77}, Franco Giulianini³⁹, Mark O. Goodarzi^{78,79}, Harald Grallert^{75,76,77}, Niels Grarup²⁸, Leif Groop⁸⁰, Megan L. Grove²⁶, Vilmundur Gudnason^{59,81}, Torben Hansen^{28,82}, Tamara B. Harris⁸³, Caroline Hayward⁸⁴, Joel N. Hirschhorn^{3,85}, Oddgeir L. Holmen^{86,87}, Jennifer Huffman⁸⁴, Yong Huo⁸⁸, Kristian Hveem⁸⁹, Sehrish Jabeen¹⁰, Anne U Jackson²⁵, Johanna Jakobsdottir^{59,81}, Marjo-Riitta Jarvelin¹³, Gorm B Jensen⁹⁰, Marit E. Jørgensen^{91,92}, J. Wouter Jukema^{93,94}, Johanne M. Justesen²⁸, Pia R. Kamstrup²², Stavroula Kanoni⁹⁵, Fredrik Karpe^{96,97}, Frank Kee⁹⁸, Amit V. Khera^{3,11}, Derek Klarin^{3,11,99}, Heikki A. Koistinen^{100,101,102}, Jaspal S Kooner^{37,38,103}, Charles Kooperberg¹⁰⁴, Kari Kuulasmaa¹⁰⁰, Johanna Kuusisto¹⁰⁵, Markku Laakso¹⁰⁵, Timo Lakka^{106,107,108}, Claudia Langenberg¹⁰⁹, Anne Langsted^{22,23}, Lenore J. Launer⁸³, Torsten Lauritzen¹¹⁰, David CM Liewald^{49,50}, Li An Lin⁶⁵, Allan Linneberg^{111,112,113}, Ruth J.F. Loos^{29,114}, Yingchang Lu²⁹, Xiangfeng Lu^{41,115}, Reedik Mägi⁶⁰, Anders Malarstig^{116,117}, Ani Manichaikul¹¹⁸, Alisa K. Manning^{3,11,119}, Pekka Mäntyselkä¹²⁰, Eirini Marouli⁹⁵, Nicholas GD Masca^{121,122}, Andrea Maschio³³, James B. Meigs^{3,119,123}, Olle Melander¹²⁴, Andres Metspalu⁶⁰, Andrew P Morris^{8,125}, Alanna C. Morrison²⁶, Antonella Mulas³³, Martina Müller-Nurasyid^{126,127,128}, Patricia B. Munroe^{34,129}, Matt J Neville⁹⁶, Jonas B. Nielsen⁴¹, Sune F Nielsen^{22,23}, Børge G Nordestgaard^{22,23}, Jose M. Ordovas^{130,131,132}, Roxana Mehran¹⁹, Christoper J. O'Donnell^{99,133}, Marju Orho-

Melander¹²⁴, Cliona M. Molony¹³⁴, Pieter Muntendam¹³⁵, Sandosh Padmanabhan⁵⁴, Colin NA Palmer⁴⁵, Dorota Pasko⁶⁹, Aniruddh P. Patel^{3,11,133,136}, Oluf Pedersen²⁸, Markus Perola^{100,137}, Annette Peters^{75,76,127}, Charlotta Pisinger¹¹³, Giorgio Pistis³³, Ozren Polasek^{138,139}, Neil Poulter¹⁴⁰, Bruce M. Psaty^{24,141,142}, Daniel J. Rader¹⁴³, Asif Rasheed¹⁰, Rainer Rauramaa^{107,108}, Dermot Reilly¹³⁴, Alex P. Reiner^{104,144}, Frida Renström^{66,145}, Stephen S Rich¹¹⁸, Paul M Ridker³⁹, John D. Rioux⁵⁵, Neil R Robertson^{8,96}, Dan M. Roden⁵³, Jerome I. Rotter⁴², Igor Rudan¹³⁹, Veikko Salomaa¹⁰⁰, Nilesh J Samani^{121,122}, Serena Sanna³³, Naveed Sattar^{54,96}, Ellen M. Schmidt¹⁴⁶, Robert A. Scott¹⁰⁹, Peter Sever¹⁴⁰, Raquel S. Sevilla¹⁴⁷, Christian M. Shaffer⁵³, Xueling Sim^{25,148}, Suthesh Sivapalaratnam¹⁴⁹, Kerrin S Small¹⁵⁰, Albert V. Smith^{59,81}, Blair H Smith^{151,152}, Sangeetha Somayajula¹⁵³, Lorraine Southam^{8,154}, Timothy D Spector¹⁵⁰, Elizabeth K. Speliotes^{146,155}, John M Starr^{49,156}, Kathleen E Stirrups^{95,157}, Nathan Stitzel^{158,159}, Konstantin Strauch^{76,160}, Heather M Stringham²⁵, Praveen Surendran⁵, Hayato Tada¹⁶¹, Alan R. Tall¹⁶², Hua Tang¹⁶³, Jean-Claude Tardif^{55,57}, Kent D Taylor⁴², Stella Trompet^{93,164}, Philip S. Tsao^{16,17}, Jaakko Tuomilehto^{165,166,167,168}, Anne Tybjaerg-Hansen^{70,71}, Natalie R van Zuydam^{8,45}, Anette Varbo^{22,23}, Tibor V Varga⁶⁶, Jarmo Virtamo¹⁰⁰, Melanie Waldenberger^{76,77}, Nan Wang¹⁶², Nick J. Wareham¹⁰⁹, Helen R Warren^{34,129}, Peter E. Weeke^{53,169}, Joshua Weinstock²⁵, Jennifer Wessel^{170,171}, James G. Wilson¹⁷², Peter W. F. Wilson^{173,174}, Ming Xu¹⁷⁵, Hanieh Yaghootkar⁶⁹, Robin Young⁵, Eleftheria Zeggini¹⁵⁴, He Zhang⁴¹, Neil S. Zheng¹⁷⁶, Weihua Zhang³⁶, Yan Zhang⁸⁸, Wei Zhou¹⁴⁶, Yanhua Zhou², Magdalena Zoledziewska³³, Charge Diabetes Working Group, The EPIC-InterAct consortium, EPIC-CVD Consortium, GOLD Consortium, VA Million Veteran Program, Joanna MM Howson^{5,†}, John Danesh^{5,6,154,†}, Mark I McCarthy^{8,96,97,†}, Chad Cowan^{4,177,†}, Goncalo Abecasis^{25,†}, Panos Deloukas^{95,178,†}, Kiran Musunuru^{7,†}, Cristen J. Willer^{41,72,146,†,*}, and Sekar Kathiresan^{3,11,133,136,†,*}

Affiliations

¹Department of Public Health Sciences, Institute of Personalized Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA ²Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA ³Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA ⁴Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA ⁵MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ⁶The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge, Cambridge, UK ⁷Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA ⁸Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK ⁹Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA ¹⁰Center for Non-Communicable Diseases, Karachi, Pakistan ¹¹Center for Genomic Medicine,

Massachusetts General Hospital, Boston, Massachusetts, USA ¹²ICDDR, B, Mohakhali, Dhaka, Bangladesh ¹³Imperial College London, London, UK ¹⁴Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, Lille, France ¹⁵Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Strasbourg, France ¹⁶VA Palo Alto Health Care System, Palo Alto, California, USA ¹⁷Department of Medicine, Stanford University School of Medicine, Stanford, California, USA ¹⁸Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA ¹⁹Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine, Mount Sinai, New York, New York, USA ²⁰Department of Medicine, Baylor College of Medicine, Houston, Texas, USA ²¹Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark ²²Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark ²³Faculty of Health and Medical Sciences, University of Denmark, Denmark ²⁴Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA ²⁵Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA ²⁶Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA ²⁷Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA ²⁸The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ²⁹The Charles Bronfman Institute for Personalized Medicine, Ichan School of Medicine at Mount Sinai, New York, New York, USA ³⁰Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark ³¹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark ³²Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, UK ³³Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy ³⁴Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary University of London, Charterhouse Square, London, UK ³⁵The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK ³⁶Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London, UK ³⁷Department of Cardiology, Ealing Hospital NHS Trust, Uxbridge Road, Southall, Middlesex, UK ³⁸Imperial College Healthcare NHS Trust, London, UK ³⁹Division of Preventive Medicine, Boston, Massachusetts, USA ⁴⁰Harvard Medical School, Boston, Massachusetts, USA ⁴¹Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA ⁴²The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Departments of Pediatrics and Medicine, Los Angeles, California, USA ⁴³Medical Department, Lillebaelt Hospital, Vejle, Denmark ⁴⁴NHLBI

Framingham Heart Study, Framingham, Massachusetts, USA ⁴⁵Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK ⁴⁶Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy ⁴⁷Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA ⁴⁸Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA ⁴⁹Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK ⁵⁰Department of Psychology, University of Edinburgh, Edinburgh, UK ⁵¹Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece ⁵²Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA ⁵³Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA ⁵⁴British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK ⁵⁵Montreal Heart Institute, Montreal, Quebec, Canada ⁵⁶Université de Montréal Beaulieu-Saucier Pharmacogenomics Center, Montreal, Quebec, Canada ⁵⁷Université de Montréal, Montreal, Quebec, Canada ⁵⁸Department of Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland ⁵⁹The Icelandic Heart Association, Kopavogur, Iceland ⁶⁰Estonian Genome Center, University of Tartu, Tartu, Estonia ⁶¹Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA ⁶²Research Centre in Epidemiology and Preventive Medicine – EPIMED, Department of Medicine and Surgery, University of Insubria, Varese, Italy ⁶³Department of Epidemiology, UMR 1027- INSERM, Toulouse University-CHU Toulouse, Toulouse, France ⁶⁴University of Glasgow, Glasgow, UK ⁶⁵Institute of Molecular Medicine, the University of Texas Health Science Center at Houston, Houston, Texas, USA ⁶⁶Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden ⁶⁷Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden ⁶⁸Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA ⁶⁹Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK ⁷⁰Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark ⁷¹Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark ⁷²Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA ⁷³Department of Cardiology, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Beijing, China ⁷⁴National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA ⁷⁵German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany ⁷⁶Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany ⁷⁷Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany ⁷⁸Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA ⁷⁹Division of Endocrinology, Diabetes and Metabolism, Cedars-

Sinai Medical Center, Los Angeles, California, USA ⁸⁰Department of Clinical Sciences, Diabetes and Endocrinology, Clinical Research Centre, Lund University, Malmö, Sweden ⁸¹The University of Iceland, Reykjavik, Iceland ⁸²Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark ⁸³Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland, USA ⁸⁴Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK ⁸⁵Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA, USA ⁸⁶Department of Public Health and General Practice, HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway ⁸⁷St Olav Hospital, Trondheim University Hospital, 7030 Trondheim, Norway ⁸⁸Department of Cardiology, Peking University First Hospital, Beijing, China ⁸⁹K. G. Jebsen Center for Genetic Epidemiology, Dept of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway ⁹⁰The Copenhagen City Heart Study, Frederiksberg Hospital, Denmark ⁹¹Steno Diabetes Center, Gentofte, Denmark ⁹²National Institute of Public Health, Southern Denmark University, Denmark ⁹³Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands ⁹⁴The Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands ⁹⁵William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK ⁹⁶Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK ⁹⁷Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK ⁹⁸Director, UKCRC Centre of Excellence for Public Health, Queens University, Belfast, Northern Ireland ⁹⁹Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA ¹⁰⁰Department of Health, National Institute for Health and Welfare, Helsinki, Finland ¹⁰¹University of Helsinki; and Department of Medicine, and Abdominal Center: Endocrinology, Helsinki University Central Hospital, Helsinki, Finland ¹⁰²Minerva Foundation Institute for Medical Research, Helsinki, Finland ¹⁰³National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, London, UK ¹⁰⁴Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ¹⁰⁵Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland ¹⁰⁶Department of Physiology, Institute of Biomedicine, University of Eastern Finland, Kuopio Campus, Kuopio, Finland ¹⁰⁷Kuopio Research Institute of Exercise Medicine, Kuopio, Finland ¹⁰⁸Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland ¹⁰⁹MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK ¹¹⁰Department of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark ¹¹¹Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark ¹¹²Department of Clinical Medicine, Faculty of Health and Medical

Sciences, University of Copenhagen, Copenhagen, Denmark ¹¹³Research Center for Prevention and Health, Capital Region of Denmark, Copenhagen, Denmark ¹¹⁴The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, New York, USA ¹¹⁵State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ¹¹⁶Cardiovascular Genetics and Genomics Group, Cardiovascular Medicine Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden ¹¹⁷Pharmatherapeutics Clinical Research, Pfizer Worldwide R&D, Sollentuna, Sweden ¹¹⁸Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA ¹¹⁹Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA ¹²⁰Unit of Primary Health Care, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland ¹²¹Department of Cardiovascular Sciences, University of Leicester, Leicester, UK ¹²²NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester UK ¹²³Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA ¹²⁴Department of Clinical Sciences, University Hospital Malmö Clinical Research Center, Lund University, Malmö, Sweden ¹²⁵Department of Biostatistics, University of Liverpool, Liverpool, UK ¹²⁶Department of Medicine I, Ludwig-Maximilians-University, Munich, Germany ¹²⁷DZHK German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany ¹²⁸Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany ¹²⁹NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK ¹³⁰Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Investigation, Madrid, Spain ¹³¹IMDEA-Alimentacion, Madrid, Spain ¹³²Nutrition and Genomics Laboratory, Jean Mayer-USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA ¹³³Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA ¹³⁴Genetics, Merck Sharp & Dohme Corp., Kenilworth, New Jersey, USA ¹³⁵G3 pharmaceuticals, Lexington, Massachusetts, USA ¹³⁶Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA ¹³⁷Institute of Molecular Medicine FIMM, University of Helsinki, Finland ¹³⁸Faculty of Medicine, University of Split, Split, Croatia ¹³⁹Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK ¹⁴⁰International Centre for Circulatory Health, Imperial College London, UK ¹⁴¹Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA ¹⁴²Departments of Epidemiology and Health Services, University of Washington, Seattle, Washington, USA ¹⁴³Departments of Genetics, Medicine, and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA ¹⁴⁴Department of Epidemiology, University of Washington, Seattle, Washington, USA ¹⁴⁵Department of Biobank Research, Umeå University, Umeå, Sweden ¹⁴⁶Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA ¹⁴⁷Imaging, Merck Sharp & Dohme Corp., Kenilworth, New Jersey, USA ¹⁴⁸Saw Swee Hock School of Public

Health, National University of Singapore, Singapore, 117549, Singapore
¹⁴⁹Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, NL ¹⁵⁰Department of Twin Research and Genetic Epidemiology, King's College London, London, UK ¹⁵¹Division of Population Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland ¹⁵²Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK ¹⁵³Scientific Informatics, Merck Sharp & Dohme Corp., Kenilworth, New Jersey, USA ¹⁵⁴Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK ¹⁵⁵Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA ¹⁵⁶Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK ¹⁵⁷Department of Haematology, University of Cambridge, Cambridge, UK ¹⁵⁸Cardiovascular Division, Departments of Medicine and Genetics, Washington University School of Medicine, St. Louis, Missouri, USA ¹⁵⁹The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA ¹⁶⁰Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany ¹⁶¹Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan ¹⁶²Division of Molecular Medicine, Department of Medicine, Columbia University, New York, New York, USA ¹⁶³Department of Genetics, Stanford University School of Medicine, Stanford, California, USA ¹⁶⁴Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands ¹⁶⁵Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland ¹⁶⁶Dasman Diabetes Institute, Dasman, Kuwait ¹⁶⁷Centre for Vascular Prevention, Danube-University Krems, Krems, Austria ¹⁶⁸Saudi Diabetes Research Group, King Abdulaziz University, Fahd Medical Research Center, Jeddah, Saudi Arabia ¹⁶⁹The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark ¹⁷⁰Department of Epidemiology, Indiana University Fairbanks School of Public Health, Indianapolis, Indiana, USA ¹⁷¹Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA ¹⁷²Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA ¹⁷³Atlanta VA Medical Center, Decatur, Georgia, USA ¹⁷⁴Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia, USA ¹⁷⁵Department of Cardiology, Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China ¹⁷⁶Yale University, New Haven, Connecticut, USA ¹⁷⁷Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA ¹⁷⁸Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia

Acknowledgments

Dajiang J Liu is partially supported by R01HG008983, R21DA040177, and R01DA037904. Gina M Peloso is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award

Number K01HL125751. Aniruddh P. Patel is recipient of research fellowship from Stanley J. Sarnoff Cardiovascular Research Foundation. Hayato Tada is supported by a grant from the Japanese Circulation Society to study in the United States. The research was supported by the National Institute for Health Research (NIHR) Exeter Clinical Research Facility, and ERC grant to Timothy M. Frayling 323195; SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC. EKS is supported by NIH grants R01 DK106621, R01 DK107904, The University of Michigan Biological Sciences Scholars Program, and The University of Michigan Department of Internal Medicine. Tim Spector is holder of an ERC Advanced Principal Investigator award. Andrew P Morris is a Wellcome Trust Senior Fellow in Basic Biomedical Science (grant number WT098017). Y. Eugene Chen is supported by HL117491 and HL129778. Santhi K. Ganesh is supported by HL122684. Paul L. Auer was supported by NHLBI R21 HL121422-02. Claudia Langenberg, Nick J. Wareham, and Robert A. Scott acknowledge funding from the Medical Research Council, UK (MC_UU_12015/1). John Danesh is a British Heart Foundation Professor, European Research Council Senior Investigator, and National Institute for Health Research (NIHR) Senior Investigator. Cristen J. Willer is supported by HL094535 and HL109946. SK is supported by a research scholar award from the Massachusetts General Hospital, the Donovan Family Foundation, and R01 HL127564; he has received grants from Bayer Healthcare, Aegerion Pharmaceuticals, and Regeneron Pharmaceuticals; and consulting fees from Merck, Novartis, Sanofi, AstraZeneca, Alnylam Pharmaceuticals, Leerink Partners, Noble Insights, Quest Diagnostics, Genomics PLC, and Eli Lilly and Company; and holds equity in San Therapeutics and Catabasis Pharmaceuticals.

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

This research has been conducted using the UK Biobank Resource.

All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding support for participating studies in the meta-analysis can be found in the Supplemental Material.

References

1. Loh PR, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet.* 2015; 47:284–90. [PubMed: 25642633]
2. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature.* 2010; 466:707–13. [PubMed: 20686565]
3. Asselbergs FW, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet.* 2012; 91:823–38. [PubMed: 23063622]
4. Global Lipids Genetics Consortium. et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet.* 2013; 45:1274–83. [PubMed: 24097068]
5. Albrechtsen A, et al. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. *Diabetologia.* 2013; 56:298–310. [PubMed: 23160641]
6. Peloso GM, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *American Journal of Human Genetics.* 2014; 94:223–232. [PubMed: 24507774]
7. Surakka I, et al. The impact of low-frequency and rare variants on lipid levels. *Nat Genet.* 2015; 47:589–97. [PubMed: 25961943]
8. Tang CS, et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. *Nat Commun.* 2015; 6:10206. [PubMed: 26690388]
9. Musunuru K, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature.* 2010; 466:714–9. [PubMed: 20686566]
10. Burkhardt R, et al. Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. *J Clin Invest.* 2010; 120:4410–4. [PubMed: 21084752]
11. Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet.* 2012; 380:572–80. [PubMed: 22607825]
12. Do R, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet.* 2013; 45:1345–52. [PubMed: 24097064]
13. Lu X, et al. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants contributing to lipid levels and coronary artery disease. *Nature Genetics.* 2017

14. Feng S, Liu D, Zhan X, Wing MK, Abecasis GR. RAREMETAL: fast and powerful meta-analysis for rare variants. *Bioinformatics*. 2014; 30:2828–9. [PubMed: 24894501]
15. Liu DJ, et al. Meta-analysis of gene-level tests for rare variant association. *Nat Genet*. 2014; 46:200–4. [PubMed: 24336170]
16. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015; 518:197–206. [PubMed: 25673413]
17. Holmen OL, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. *Nat Genet*. 2014; 46:345–51. [PubMed: 24633158]
18. Klarin D. Genetics of lipids in >300,000 participants in the Million Veteran Program. Under Review.
19. Shen X, et al. Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes. *Atherosclerosis*. 2012; 222:154–7. [PubMed: 22398276]
20. Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005; 365:1054–61. [PubMed: 15781101]
21. James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005; 434:1144–8. [PubMed: 15793561]
22. Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med*. 2005; 352:1779–90. [PubMed: 15858187]
23. Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005; 7:387–97. [PubMed: 15837627]
24. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014; 371:2488–98. [PubMed: 25426837]
25. Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017; 377:111–121. [PubMed: 28636844]
26. Mullally A, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. *Cancer Cell*. 2010; 17:584–96. [PubMed: 20541703]
27. Lellek H, et al. Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex. *J Biol Chem*. 2000; 275:19848–56. [PubMed: 10781591]
28. Mehta A, Kinter MT, Sherman NE, Driscoll DM. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. *Mol Cell Biol*. 2000; 20:1846–54. [PubMed: 10669759]
29. Galloway CA, Ashton J, Sparks JD, Mooney RA, Smith HC. Metabolic regulation of APOBEC-1 complementation factor trafficking in mouse models of obesity and its positive correlation with the expression of ApoB protein in hepatocytes. *Biochim Biophys Acta*. 2010; 1802:976–85. [PubMed: 20541607]
30. Galanello R, Origa R. Beta-thalassemia. *Orphanet J Rare Dis*. 2010; 5:11. [PubMed: 20492708]
31. Fessas P, Stamatoyannopoulos G, Keys A. Serum-cholesterol and thalassemia trait. *Lancet*. 1963; 1:1182–3. [PubMed: 13944960]
32. Sidore C, et al. Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. *Nat Genet*. 2015; 47:1272–81. [PubMed: 26366554]
33. Chen W, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2010; 107:7401–6. [PubMed: 20385819]
34. Neale BM, et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). *Proc Natl Acad Sci U S A*. 2010; 107:7395–400. [PubMed: 20385826]
35. Wang YF, et al. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration. *Sci Rep*. 2015; 5:15711. [PubMed: 26503844]

36. Cheng CY, et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. *Nat Commun.* 2015; 6:6063. [PubMed: 25629512]
37. Momozawa Y, et al. Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population. *Hum Mol Genet.* 2016; 25:5027–5034. [PubMed: 28173125]
38. Lotta LA, et al. Association between low-Density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. *JAMA.* 2016; 316:1383–1391. [PubMed: 27701660]
39. Schmidt AF, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. *Lancet Diabetes Endocrinol.* 2016
40. Ference BA, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. *N Engl J Med.* 2016; 375:2144–2153. [PubMed: 27959767]
41. Mahajan A, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *bioRxiv.* 2017
42. Myocardial Infarction Genetics & CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, SVEP1 and the risk of coronary disease. *N Engl J Med.* 2016; 374:1134–44. [PubMed: 26934567]
43. Goldstein JI, et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics.* 2012; 28:2543–5. [PubMed: 22843986]
44. Grove ML, et al. Best practices and joint calling of the HumanExome BeadChip: The CHARGE Consortium. *PLoS One.* 2013; 8:e68095. [PubMed: 23874508]
45. Tennessen JA, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science.* 2012; 337:64–9. [PubMed: 22604720]
46. 1000 Genomes Project Consortium. et al. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491:56–65. [PubMed: 23128226]
47. Zhan X, Liu DJ. SEQMINER: An R-Package to Facilitate the Functional Interpretation of Sequence-Based Associations. *Genet Epidemiol.* 2015; 39:619–23. [PubMed: 26394715]
48. Fritsche LG, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet.* 2016; 48:134–43. [PubMed: 26691988]
49. Morris AP, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet.* 2012; 44:981–90. [PubMed: 22885922]
50. Gaulton KJ, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. *Nat Genet.* 2015; 47:1415–25. [PubMed: 26551672]
51. Fuchsberger C, et al. The genetic architecture of type 2 diabetes. *Nature.* 2016; 536:41–7. [PubMed: 27398621]
52. The UK Biobank. Genotyping and quality control of UK Biobank, a large-scale, extensively phenotyped prospective resource. 2015. http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UKBiobank_genotyping_QC_documentation-web.pdf
53. Speliotes EK, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genet.* 2011; 7:e1001324. [PubMed: 21423719]
54. Baber U, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. *J Am Coll Cardiol.* 2015; 65:1065–74. [PubMed: 25790876]




Figure 1. A1CF p.Gly398Ser mutant leads to increased APOB100 secretion

a, Western blot showing the depletion of endogenous A1CF levels via CRISPR/Cas9 system in both Huh7 and HepG2 cells. **b** and **c**, Lack of A1CF leads to reduced APOB100 secretion in Huh7 (**b**) and HepG2 (**c**) human hepatoma cells. **d**, Recombinantly overexpressed A1CF p.Gly398Ser variant led to significantly increased APOB100 secretion compared to A1CF or GFP control in both Huh7 wild-type and A1CF knockout cells (labeled as A1CF KO), respectively. The bars of mean value and error bars of SD are showed in **b**, **c** and **d** from experiments with biological replicates, N=6. Statistically significant differences are marked (* $p < 0.05$, ** $p < 0.01$).




Figure 2. Association of genetically-lowered triglycerides by LPL variants with a range of phenotypes

Estimates were derived in UK Biobank using logistic regression, adjusting for age, sex, ten principal components of ancestry and an indicator variable for array type. Effect estimates are for a 1 standard deviation lower plasma triglycerides. Definitions for all outcomes are provided in Supplementary Table 20.

Table 1

Protein-altering variants at novel loci associated with lipid levels

Chromosome:position (hg19)	rs ID	Alleles (reference/alternative)	Gene	Protein change	N	Frequency alternative allele	Trait	P value	Beta	SE
Total Cholesterol										
2:101627925	rs1062062	C/T	<i>TBC1D8</i>	p.Gly954Arg	292898	0.12	TC	1×10 ⁻⁷	-0.021	0.0040
4:69343287	rs976002	A/G	<i>TM6RS11E</i>	p.Tyr303Cys	293961	0.23	TC LDL-C	5×10 ⁻²⁰ 3×10 ⁻¹²	0.029, 0.023	0.0031, 0.0033
4:155489608	rs6054	C/T	<i>FGB</i>	p.Pro206Leu	307997	0.0038	TC TG	5×10 ⁻¹² 3×10 ⁻¹¹	0.14, 0.14	0.021, 0.021
9:5073770	rs77375493	G/T	<i>JAK2</i>	p.Val617Phe	188412	0.0011	TC LDL-C	1×10 ⁻¹¹ 2×10 ⁻⁹	-0.32, -0.30	0.047, 0.049
9:117166246	rs2274159	A/G	<i>DEFB31</i>	p.Val400Ala	319677	0.48	TC	2×10 ⁻⁷	0.013	0.0026
17:8216468	rs871841	T/C	<i>ARHGGEF15</i>	p.Leu277Pro	298725	0.52	TC	2×10 ⁻⁸	0.015	0.0026
19:18304700	rs874628	A/G	<i>MPV17L2</i>	p.Met72Val	319677	0.26	TC	2×10 ⁻⁷	0.015	0.0029
LDL Cholesterol										
1:155106227	rs4745	A/T	<i>EFNA1</i>	p.Asp137Val	291361	0.49	LDL-C	5×10 ⁻⁸	-0.015	0.0027
4:187120211	rs13146272	C/A	<i>CYP4V2</i>	p.Gln259Lys	295826	0.62	LDL-C	1×10 ⁻⁷	-0.015	0.0027
5:176520243	rs351855	G/A	<i>FGFR4</i>	p.Gly388Arg	233058	0.29	LDL-C	4×10 ⁻⁸	-0.018	0.0033
9:139368953	rs3812594	G/A	<i>SEC16A</i>	p.Arg1039Cys	293723	0.24	LDL-C	2×10 ⁻⁸	-0.018	0.0031
10:118397971	rs10885997	A/G	<i>PNLIPRP2</i>	p.Gln387Arg	258146	0.41	LDL-C	9×10 ⁻⁸	0.015	0.0029
10:124610027	rs1891110	G/A	<i>FAM24B</i>	p.Pro2Leu	295826	0.55	LDL-C TC	8×10 ⁻¹⁵ 2×10 ⁻¹³	0.021, 0.019	0.0026, 0.0025
12:72179446	rs61754230	C/T	<i>RAB21</i>	p.Ser224Phe	292762	0.015	LDL-C	1×10 ⁻⁷	0.057	0.011
14:94844947	rs28929474	C/T	<i>SERPINA1</i>	p.Glu366Lys	290263	0.015	LDL-C TC	4×10 ⁻¹⁴ 6×10 ⁻¹⁴	0.081, 0.078	0.011, 0.010
17:26694861	rs704	G/A	<i>VTN</i>	p.Thr400Met	295826	0.49	LDL-C TC	6×10 ⁻¹⁶ 1×10 ⁻⁸	0.021, 0.015	0.0026, 0.0025
19:42584958	rs201596848	C/T	<i>ZNF574</i>	p.Arg734Cys	273744	0.0014	LDL-C	5×10 ⁻¹²	-0.255	0.037
Triglycerides										
2:202122995	rs3769823	A/G	<i>CASP8</i>	p.Lys144Arg	295956	0.69	TG	1×10 ⁻⁹	0.017	0.0028
5:131008194	rs26008	T/C	<i>FNIP1</i>	p.Gln620Arg	305699	0.92	TG	5×10 ⁻⁹	-0.028	0.0048

Chromosome:position (hg19)	rs ID	Alleles (reference/alternative)	Gene	Protein change	N	Frequency alternative allele	Trait	P value	Beta	SE
10:52573772	rs41274050	C/T	<i>A/CF</i>	p.Gly398Ser	299984	0.0072	TG TC	4×10 ⁻¹¹ 1×10 ⁻⁷	0.10, 0.08	0.015, 0.015
13:45970147	rs138358301	A/G	<i>SLC25A30</i>	p.Phe280Leu	301087	0.0035	TG	3×10 ⁻¹¹	0.15	0.022
15:40751555	rs3803357	C/A	<i>BAHDI</i>	p.Gln298Lys	305699	0.55	TG	1×10 ⁻¹⁰	-0.017	0.0026
17:17409560	rs7946	C/T	<i>PEMT</i>	p.Val212Met	304420	0.67	TG	1×10 ⁻⁸	-0.016	0.0029
20:56140439	rs41302559	G/A	<i>PCK1</i>	p.Arg483Gln	299984	0.0021	TG	9×10 ⁻⁸	-0.154	0.029
22:17625915	rs35665085	G/A	<i>CECR5</i>	p.Thr149Met	302582	0.050	TG	5×10 ⁻⁸	0.032	0.0059
HDL Cholesterol										
2:272203	rs11553746	C/T	<i>ACPI</i>	p.Thr95Ile	313148	0.33	HDL-C	5×10 ⁻⁸	0.015	0.0027
2:54482553	rs17189743	G/A	<i>TSPYL6</i>	p.Arg246Cys	314415	0.029	HDL-C	2×10 ⁻⁷	0.040	0.0076
2:179309165	rs75862065	G/A	<i>PRKRA</i>	p.Pro116Leu	105490	0.29	HDL-C	2×10 ⁻⁷	0.026	0.0050
3:48229366	rs146179438	C/A	<i>CDC25A</i>	p.Gln25His	288306	0.020	HDL-C	3×10 ⁻¹¹	-0.063	0.0095
5:176637576	rs28932178	T/C	<i>NSD1</i>	p.Ser457Pro	310567	0.17	HDL-C	8×10 ⁻⁹	0.020	0.0035
11:64031241	rs35169799	C/T	<i>PLCB3</i>	p.Ser778Leu	314415	0.060	HDL-C TG	4×10 ⁻¹³ , 3×10 ⁻¹²	-0.039, 0.038	0.0054, 0.0055
11:68703959	rs622082	A/G	<i>IGHMBP2</i>	p.Thr671Ala	316391	0.31	HDL-C	6×10 ⁻¹⁰	-0.017	0.0028
16:4755108	rs78074706	G/A	<i>ANKK3</i>	p.Arg286Trp	315298	0.022	HDL-C	1×10 ⁻⁹	-0.053	0.0087
16:69385641	rs76116020	A/G	<i>TMED6</i>	p.Phe6Leu	310822	0.033	HDL-C	7×10 ⁻⁹	-0.041	0.0071
17:40257163	rs2074158	T/C	<i>DHX58</i>	p.Gln425Arg	244331	0.19	HDL-C	1×10 ⁻⁷	-0.020	0.0038

Table 2

Impact of genes involved in hepatic production of triglyceride-rich lipoproteins (*PNPLA3*, *TM6SF2*) versus lipolysis pathway genes (*LPL*, *ANGPTL4*) on related metabolic traits - blood lipids, fatty liver, type 2 diabetes, and coronary artery disease.

Gene	<i>LPL</i>	<i>ANGPTL4</i>	<i>PNPLA3</i>	<i>TM6SF2</i>
Variant	p.Ser474Ter	p.Glu40Lys	p.Ile148Met	p.Glu167Lys
Effect Allele	Ter	Lys	Met	Lys
Frequency	10%	2%	23%	7%
Blood triglycerides				
Effect Direction	↓	↓	↓	↓
Beta	-0.18	-0.27	-0.018	-0.12
(CI)	(-0.19,-0.17)	(-0.29,-0.25)	(-0.024,-0.012)	(-0.13,-0.11)
P	$P < 1 \times 10^{-323}$	$P = 4 \times 10^{-175}$	$P = 4 \times 10^{-9}$	$P = 4 \times 10^{-125}$
Blood LDL cholesterol				
Effect Direction	-	↓	↓	↓
Beta	0.013	-0.004	-0.018	-0.103
(CI)	(0.0052,0.021)	(-0.024,0.016)	(-0.024,-0.012)	(-0.11,-0.093)
P	$P = 0.005$	$P = 0.70$	$P = 1 \times 10^{-8}$	$P = 7 \times 10^{-93}$
Fatty liver				
Effect Direction	-	-	↑	↑
Beta *	0.026	0.112	-0.25	-0.25
(CI)	(-0.035,0.087)	(-0.021,0.25)	(-0.29,-0.2)	(-0.32,-0.18)
P	$P = 0.41$	$P = 0.10$	$P = 2 \times 10^{-30}$	$P = 5 \times 10^{-12}$
Type 2 diabetes				
Effect Direction	↓	↓	↑	↑
OR	0.95	0.91	1.04	1.07
(CI)	(0.93,0.97)	(0.83,0.99)	(1.03,1.05)	(1.05,1.09)
P	$P = 7 \times 10^{-9}$	$P = 1 \times 10^{-4}$	$P = 2 \times 10^{-10}$	$P = 5 \times 10^{-12}$
Coronary artery disease				
Effect Direction	↓	↓	↓	↓
OR	0.93	0.85	0.96	0.95
(CI)	(0.9,0.96)	(0.8,0.9)	(0.94,0.97)	(0.93,0.98)
P	$P = 4 \times 10^{-7}$	$P = 2 \times 10^{-10}$	$P = 4 \times 10^{-8}$	$P = 3 \times 10^{-4}$

* A negative beta reflects liver attenuation on computed tomography which is indicative of *higher* liver fat

Association results for lipids are derived from present study

Association results for type 2 diabetes are from⁴¹

Association results for coronary artery disease are from⁴²